Core Points - Zhendé Medical (603301) experienced a significant stock price increase, closing at 38.1 yuan on September 15, 2025, which is a 6.9% rise from the previous trading day, with a total market capitalization of 10.152 billion yuan [1] - The stock exhibited abnormal trading fluctuations, with a cumulative price increase deviation exceeding 20% over three consecutive trading days [1] - The company confirmed that there are no undisclosed significant matters apart from the disclosed share transfer [1] Summary by Sections Stock Performance - On September 15, 2025, Zhendé Medical's stock opened at 35.79 yuan, reached a high of 39.19 yuan, and a low of 33.77 yuan, with a trading volume of 1.109 billion yuan and a turnover rate of 11.48% [1] Share Transfer - The controlling shareholder, Zhejiang Zhendé, and its wholly-owned subsidiary, Xuchang Garden, plan to transfer a total of 13,322,560 shares (5.00% of total share capital) at a price of 26.74 yuan per share, totaling approximately 356.25 million yuan [1] - This share transfer is subject to compliance review by the Shanghai Stock Exchange and the completion of share transfer registration, indicating some uncertainty [1] Company Operations - The company stated that its production and operations are normal, with no significant changes in the external business environment or industry policies [1] - There were no major media reports or market rumors identified that could have significantly impacted the company's stock price during the fluctuation period [1] - The board of directors confirmed that there are no undisclosed matters that should have been disclosed [1]

（文章来源：证券日报） 证券日报网讯 9月15日晚间，振德医疗发布公告称，公司股票于2025年9月11日、9月12日、9月15日连 续3个交易日内收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动情形。经公司自查，并书面 发函询问控股股东及实际控制人，截至本公告披露日，确认不存在应披露而未披露的重大事项或重要信 息。 ...

振德医疗(603301)今日上涨6.90%，全天换手率11.48%，成交额11.09亿元，振幅16.05%。龙虎榜数据显 示，机构净卖出1.02亿元，沪股通净卖出259.22万元，营业部席位合计净买入8466.27万元。 上交所公开信息显示，当日该股因日振幅值达16.05%上榜，机构专用席位净卖出1.02亿元，沪股通净卖 出259.22万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交5.05亿元，其中，买入成交额为2.42亿 元，卖出成交额为2.63亿元，合计净卖出2028.09万元。 具体来看，今日上榜的营业部中，共有1家机构专用席位现身，即卖一，合计净卖出1.02亿元，沪股通 为第二大买入营业部及第二大卖出营业部，买入金额为5231.03万元，卖出金额为5490.25万元，合计净 卖出259.22万元。 资金流向方面，今日该股主力资金净流出2795.92万元，其中，特大单净流入374.60万元，大单资金净流 出3170.52万元。近5日主力资金净流入1.71亿元。 融资融券数据显示，该股最新（9月12日）两融余额为2.42亿元，其中，融资余额为2.42亿元，融券余额 为53.10万元。近5 ...

二、公司关注并核实的相关情况 证券代码：603301 证券简称：振德医疗 公告编号：2025-034 振德医疗用品股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、振德医疗用品股份有限公司(以下简称:"公司"、"本公司") 股票于 2025 年 9 月 11 日、9 月 12 日、9 月 15 日连续 3 个交易日内 收盘价格涨幅偏离值累计超过 20%,根据《上海证券交易所交易规则》 的有关规定,属于股票交易异常波动情形。 2、经公司自查,并书面发函询问控股股东及实际控制人,截至本 公告披露日,确认不存在应披露而未披露的重大事项或重要信息。 3、敬请广大投资者注意投资风险。 一、股票交易异常波动的具体情况 公司股票于 2025 年 9 月 11 日、9 月 12 日、9 月 15 日连续 3 个 交易日内收盘价格涨幅偏离值累计超过 20%,根据《上海证券交易所 交易规则》的有关规定,属于股票交易异常波动情形。 根据上海证券交易所相关规定,公司对相关问题进行了必要核实。 现说 ...

关于《振德医疗用品股份有限公司股票交易异常波动 问询函》的回函 振德医疗用品股份有限公司: 本人于 2025 年 9 月 15 日收到贵公司发来的《振德医疗用品股份 有限公司股票交易异常波动问询函》,经自查核实,回复如下: 本人控制的浙江振德控股有限公司(以下简称"浙江振德")及 其全资子公司许昌振德园林绿化工程有限公司(以下简称"许昌园林") 于 2025 年 9 月 10 日与孙纪木、中国工商银行股份有限公司绍兴分 行签署了《关于振德医疗用品股份有限公司股份转让协议》,浙江振 德、许昌园林拟将其持有的合计 13,322,560 股贵公司无限售条件流通 股(占贵公司总股本 5.00%)通过协议转让的方式以人民币 26.74 元/ 股的价格转让给孙纪木(其中浙江振德拟转让 1,548,620 股,占贵公 司总股本的 0.58%;许昌园林拟转让 11,773,940 股,占贵公司总股本 的 4.42%),转让价款共计人民币 356,245,254.40 元。振德医疗已于 2025年9月 11日在上海证券交易所网站披露该事项详细内容。 本次协议转让事项尚需履行上海证券交易所合规性审核,并在中 国证券登记结算有限责 ...

Group 1 - The stock of Zhendemedical increased by 6.90% today, with a trading volume of 1.109 billion yuan and a turnover rate of 11.48% [1] - The post-market data shows that the Shanghai Stock Connect special seat bought 52.31 million yuan and sold 54.90 million yuan [1] - One institutional special seat had a net sell of 102 million yuan [1]

Group 1 - The core viewpoint of the news is the performance and financial metrics of Zhendemedical, which saw a stock price increase of 5.08% to 37.45 CNY per share, with a trading volume of 1.007 billion CNY and a turnover rate of 10.47%, leading to a total market capitalization of 9.979 billion CNY [1] - Zhendemedical, established on August 18, 1994, and listed on April 12, 2018, specializes in the production, research, and sales of medical dressings, with its main business revenue composition being: surgical infection control 43.04%, basic care 20.46%, ostomy and modern wound care 18.59%, pressure treatment and fixation 10.75%, infection control protection 6.58%, and others 0.58% [1] Group 2 - From the perspective of major fund holdings, Xiangcai Fund has a significant position in Zhendemedical, with its Xiangcai Medical Health Mixed A Fund (019958) increasing its holdings by 10,000 shares to a total of 40,000 shares, representing 4.59% of the fund's net value, ranking as the eighth largest holding [2] - The Xiangcai Medical Health Mixed A Fund (019958) was established on December 26, 2023, with a latest scale of 13.2808 million CNY, achieving a year-to-date return of 50.36%, ranking 846 out of 8246 in its category, and a one-year return of 67.97%, ranking 1687 out of 8054 [2] Group 3 - The fund manager of Xiangcai Medical Health Mixed A Fund is Zhang Quan, who has been in the position for 1 year and 265 days, managing total assets of 18.3775 million CNY, with the best fund return during his tenure being 74.42% and the worst being 73.66% [3]

Core Insights - Zhendemedical's trading volume reached 1.004 billion RMB, marking the highest level since December 23, 2020 [2] - The latest stock price increased by 4.88%, with a turnover rate of 10.45% [2] - The previous trading day's total transaction volume for the stock was 237 million RMB [2] Company Overview - Zhendemedical was established on August 18, 1994, with a registered capital of 2.66451202 billion RMB [2]

Core Viewpoint - The stock price of Zhendemedical (603301.SH) has surged, achieving three limit-up days in four trading sessions, primarily due to the strategic investment by steel magnate Sun Jimu [2][3]. Group 1: Stock Performance - Zhendemedical's stock price opened high and reached the limit-up within four minutes on September 12, marking its third limit-up in four trading days [2]. - The stock price was transferred at 26.74 CNY per share, approximately 10% lower than the previous closing price of 29.71 CNY [3]. Group 2: Share Transfer Details - The controlling shareholder, Zhejiang Zhendemedical Holdings Co., Ltd., and its subsidiary plan to transfer a total of 5% of the company's shares to Sun Jimu for a total consideration of 356 million CNY [3]. - The share transfer includes 1,332,600 shares, with Zhejiang Zhendemedical transferring 154,860 shares and its subsidiary transferring 1,177,390 shares [3][4]. Group 3: Company Background - Zhendemedical specializes in the production, research, and sales of medical dressings, with products distributed in over 70 countries and regions, generating approximately 60% of its revenue from overseas markets [3][8]. - The company has established a strong market presence, covering over 9,200 hospitals in China, including more than 1,200 top-tier hospitals [8][9]. Group 4: Financial Performance - Zhendemedical's net profit has shown volatility, with figures of 596 million CNY, 681 million CNY, 198 million CNY, and 385 million CNY from 2021 to 2024, and a net profit of 128 million CNY in the first half of 2025 [9][10]. - The company has consistently paid dividends since its listing in 2018, distributing a total of 1.46 billion CNY in cash dividends with an average payout ratio of 30.26% [11].

Group 1 - Junshi Bioscience's product Mindewei achieved full-channel coverage in the first half of 2025, exploring community and county market medical cooperation models [1] - Mindewei was conditionally approved for marketing by the National Medical Products Administration in January 2023, and the company has actively built a commercialization team [1] - The company has established strategic partnerships with national pharmaceutical companies and chain pharmacies, and is exploring sales models on platforms like Meituan, JD, and Alibaba Health [1] Group 2 - Changchun High-tech's subsidiary GS3-007a dry mixed suspension has received acceptance for its clinical trial application, aimed at treating pediatric growth hormone deficiency (PGHD) [2] - PGHD is a common endocrine disease in pediatrics, with an incidence rate of approximately 1 in 8600 in China, primarily caused by insufficient secretion of growth hormone-releasing hormone [2] Group 3 - Chengda Biologics has gained market access for its human rabies vaccine in Indonesia and is actively expanding into larger markets like Brazil [3] - The company's international business has shown significant growth, covering over 30 countries, and is advancing its "vaccine going abroad" strategy [3] Group 4 - Taiji Group's subsidiary has received clinical trial approval for semaglutide injection, targeting blood sugar control in adults with type 2 diabetes [4] - The indication includes patients whose blood sugar remains uncontrolled despite diet and exercise, and those at risk of major cardiovascular events [4] Group 5 - China National Pharmaceutical Group plans to strengthen accounts receivable management and establish a tracking ledger for key customers [5] - The company reported a net cash flow of -546 million yuan in the first half of 2025, a significant improvement from -743 million yuan in the same period last year [5] Group 6 - Zhend Medical expects its African production base to break even by the end of the year while actively advancing the construction of its Mexican production base [6][7] - The company is focusing on expanding into emerging markets with increasing demand for basic medical supplies and is enhancing operational efficiency in its African base [6][7]